Simplify Logo

Full-Time

Senior Scientist / Principal Scientist

Immunology

Confirmed live in the last 24 hours

Abata Therapeutics

Abata Therapeutics

11-50 employees

Develops therapies for autoimmune diseases

Biotechnology
Healthcare

Senior, Expert

Belmont, MA, USA

This is an on-site position based in the Watertown, MA office and requires regular in-office work.

Category
Lab & Research
Life Sciences
Required Skills
Communications
Requirements
  • PhD in Immunology, Molecular and Cellular Biology or a related discipline with 5 + years of post-PhD experience
  • Track record of academic excellence, including first author research publications in high caliber journals.
  • Deep knowledge and insight for integrating novel science and emerging technologies in the context of cell therapy and cellular immunology.
  • Scientific expertise in receptor engineering with proliferation, fluorescent reporter, and FACS-based read-outs
  • Technical expertise with primary human cell culture, cell engineering and multi-parameter flow cytometry
  • Experience with cell therapy development (e.g. CAR-T/TCR T cells) is preferred
  • Experience in the development of complex cell-based assays
  • Experience working with external contract labs (CROs) is a plus
  • Highly motivated, innovative, and well-organized
  • Engaging and thoughtful team player with excellent written and verbal communication skills are essential given our collaborative approach
  • Experience managing or mentoring junior scientists is desirable
  • Proven ability to work independently and effectively plan and organize work activities, prioritize tasks, and meet schedule and deadlines
Responsibilities
  • Provide expertise by advising experimental design and strategy related to immunology and cell therapy.
  • Effectively design, plan, and execute experiments from antigen-driven cell-based immunological assays, to discovering and characterizing several components of novel cell therapies using cell culture, flow cytometry, molecular biology, and genetic engineering techniques to overcome the current limitations to targeted cell therapy.
  • Drive projects in collaboration with an interdisciplinary team of scientists to develop optimized cell therapy candidates for clinical development
  • Contribute meaningfully to building out our internal efforts to advance cell therapy at the forefront of scientific innovation.
  • Identify and support external academic and commercial partnerships.
  • Communicate data and findings to the scientific team and key stakeholders within the company.
  • Help grow an early and ambitious cell therapy company developing therapeutics for currently intractable autoimmune conditions

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Abata stands out in the biotech market by targeting a specific niche of autoimmune disease patients and forming strategic partnerships, such as with ElevateBio, to enhance their research and manufacturing capabilities. The company's goal is to transform treatment options for autoimmune diseases through advanced therapies.

Company Stage

Series A

Total Funding

$60.3M

Headquarters

Cambridge, Massachusetts

Founded

2021

Growth & Insights
Headcount

6 month growth

-4%

1 year growth

-7%

2 year growth

6%
Simplify Jobs

Simplify's Take

What believers are saying

  • The appointment of industry veterans like Leonard Dragone and Ellen Cahir-McFarland strengthens Abata's leadership team, enhancing its scientific and clinical capabilities.
  • With significant funding, including a recent $95 million equity investment, Abata is well-positioned to accelerate product development and expand its operations.
  • The company's collaborative and enthusiastic work environment, driven by a mission to transform autoimmune disease treatment, offers a fulfilling and impactful career.

What critics are saying

  • The highly specialized focus on Treg cell therapies may limit Abata's market reach and make it vulnerable to advancements by competitors in broader therapeutic areas.
  • Delays in clinical trials or regulatory approvals could hinder the timely commercialization of their lead product, ABA 201, impacting revenue and growth prospects.

What makes Abata Therapeutics unique

  • Abata Therapeutics leverages the unique biology of regulatory T cells (Tregs) to develop transformative therapies for autoimmune diseases, setting it apart from traditional biotech approaches.
  • Their strategic partnership with ElevateBio ensures scalable and regulatory-compliant manufacturing processes, a critical advantage in the competitive biotech landscape.
  • Focused on niche markets like type 1 diabetes and progressive multiple sclerosis, Abata addresses unmet medical needs with innovative Treg cell therapies.